The Hub for Disease-Specific Clinical Information
Advertisement
Advertisement

Your search results for Vanessa A. Carter, BS

Ixazomib Plus Standard Therapy in Transplant-Ineligible Patients With Myeloma


TCT 2021 Is Idecabtagene Vicleucel Safe for Elderly Patients With Resistant Myeloma


Long-Term Outcomes With Standard-of-Care Strategy in Multiple Myeloma


AACR 2021 Is Novel IKZF13 Degrader Active Against Multiple Myeloma


AACR 2021: Synergistic Selinexor-Based Combinations and Companion Biomarkers in Myeloma


Risk Factors for Bloodstream Infections and Early Mortality in Multiple Myeloma


Does the First COVID-19 Vaccine Dose Offer Protection for Patients With Multiple Myeloma


ASCO 2021 Ixazomib Maintenance After HCT in High-Risk Multiple Myeloma


Can an MRD-Adaptive Study Design Help to De-escalate Therapy for Multiple Myeloma


BOSTON Trial Survival Outcomes With Selinexor in Elderly Patients With Multiple Myeloma


ICARIA-MM Updated Results With Isatuximab-Based Therapy for Resistant Myeloma


Initial Results From Cohort A of CARTITUDE-2 Ciltacabtagene Autoleucel for Progressive Myeloma


Bone-Directed Therapy in Myeloma How Often Should Bisphosphonates Be Given


SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma


SOHO 2021 ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma


Preclinical Look at Myeloma Cell Viability With Metformin Plus Lenalidomide


Combination Iberdomide and Dexamethasone for Resistant Multiple Myeloma


Early-Phase Trial of Idecabtagene Vicleucel in Resistant Multiple Myeloma


First-in-Class Targeted Cellular Therapy Under Study in Resistant Multiple Myeloma


Early-Phase Research on Daratumumab-Based Therapies for Resistant Myeloma


Update From Phase III APOLLO Trial of Daratumumab-Based Therapy for Myeloma


AACR 2022: Novel IKZF1/3 Degrader Demonstrates Activity in Multiple Myeloma


Can MGUS Status Predict the Progression of Multiple Myeloma?


ASCO 2022: Update From Cohort A of CARTITUDE-2 on Ciltacabtagene Autoleucel in Myeloma


ASCO 2022: Phase II MagnetisMM-3 Trial Focuses on Elranatamab in Resistant Myeloma


Quadruplet Therapy for Newly Diagnosed Multiple Myeloma: De-escalation Approach Under Study


Do Clinical Trials Match the Demographic and Geographic Diversity of Populations With Blood Cancers?


Infectious Complications Among Newly Diagnosed Patients With Myeloma in Latin America


Patient-Reported Outcomes of Clinical Trial Participation Versus Standard Care for Multiple Myeloma


T-Cell Engagers and Antitumor Immunity in Multiple Myeloma Therapy


Novel PANGEA Models May Improve Clinical Prediction of Disease Progression to Myeloma


Are Baseline Ocular Conditions Affected by Belantamab Mafodotin Treatment in Myeloma?


BCMA-Targeted CAR T-Cell Therapy for Older Patients With Multiple Myeloma


Can a Mutational Signature Predict Outcomes With Carfilzomib-Based Therapy for Myeloma?


SOHO 2022: Update From CARTITUDE-2 of Ciltacabtagene Autoleucel in Multiple Myeloma


ASTRO 2022: Can Radiotherapy Prevent Progression to Myeloma in Patients With Plasmacytomas?


ASH 2022: Early-Phase Trial Evaluates Elranatamab in Resistant Multiple Myeloma


ASH 2022: Phase I/II Results of CD3 Bispecific Antibody in Resistant Multiple Myeloma


ASH 2022: First-in-Human Study of Modakafusp Alfa in Resistant Multiple Myeloma


ASH 2022: Bispecific Antibody Elranatamab in Patients Under Study in Aggressive Multiple Myeloma


ASH 2022: Dexamethasone-Sparing Regimen for Elderly Patients With Multiple Myeloma


ASH 2022: Dose-Escalation Study Evaluates T-Cell–Engaging Bispecific Antibody in Resistant Myeloma


ASH 2022: Quadruplet Regimen Under Study in High-Risk Smoldering Multiple Myeloma


Tocilizumab Pretreatment Followed by Cevostamab for Resistant Myeloma


BCMA/CD19 Dual-Targeting CAR T-Cell Therapy for Multiple Myeloma


What Is the Optimal Duration of Lenalidomide Maintenance Therapy After ASCT?


Dose-Expansion Results of Mezigdomide-Based Therapy for Advanced Multiple Myeloma


CAR T-Cell Therapy After BCMA-Targeted Therapy for Resistant Multiple Myeloma


Potential Genomic Mechanisms of Resistance to Targeted Immunotherapy for Myeloma


Comparison of Standard Therapies for Transplantation-Ineligible Patients With Myeloma


Predictive Model in Multiple Myeloma: Focus on Pyroptosis-Related Genes


Immunoglobulin J Chain: Potential Target of T-Cell Receptor–Based Therapy in Myeloma


AACR 2023: Does Race Play a Role in Progression of Myeloma Among Patients Being Treated for Diabetes?


AACR 2023: Racial and Socioeconomic Influences on Access to Care in Multiple Myeloma


ASCO 2023: Preliminary Results With Teclistamab Plus Talquetamab for Resistant Multiple Myeloma


ASCO 2024: Is Belantamab Mafodotin Making a Comeback in the DREAMM-8 Myeloma Trial?


ASCO 2024: Can Idecabtagene Vicleucel Improve Outcomes in Extramedullary Multiple Myeloma?


Phase III CANOVA Study: Biomarker Subgroup Analysis in Advanced Multiple Myeloma


Addition of Beta-Blockers to Pomalidomide in Treatment of Multiple Myeloma


Efficacy of High-Dose Carfilzomib in MRD-Negative Multiple Myeloma


Rare Case of Smoldering Multiple Myeloma Coexisting With Gastrointestinal Amyloidosis


Survival Outcomes After Biochemical and Clinical Progression of Relapsed Myeloma


Can Plasma Cell–Free RNA Profiling Differentiate Myeloma From Its Premalignant Condition?


Risk of Breakthrough COVID Infection After Vaccination in Patients With Hematologic Malignancies


Does Targeting Autophagy Impact the Efficacy of Proteasome Inhibitor Treatment in Myeloma?


Novel Approach to Risk Stratification in Patients With Myeloma Harboring Translocations


Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: OMNIVORE Trial


Case Study of Rare but Aggressive Immune-Related Adverse Events in Kidney Cancer


Renal Cell Carcinoma and COVID-19 Does Surgical Delay Impact Outcomes


Palliative Care Utilization Trends in Advanced Renal Cell Carcinoma


Advanced Renal Cell Carcinoma: Dosage Studies of HIF-2α Inhibitor Underway


Immunotherapy After Nephrectomy Under Study in Localized Renal Cell Carcinoma


Germline Mutations in Early-Onset Renal Cell Carcinoma


Cabozantinib Plus Immunotherapy Under Study in Advanced Renal Cell Carcinoma


Novel HIF-2α Inhibitor Under Study in Von Hippel-Lindau–Associated Kidney Cancer


Does Metastatic Tumor Shrinkage Influence Overall Survival in Renal Cell Carcinoma


GU Symposium 2021 Updated CheckMate 9ER Results on Nivolumab Plus Cabozantinib in Kidney Cancer


Nivolumab as Neoadjuvant Therapy in High-Risk Clear Cell Renal Cell Carcinoma


Do Proton Pump Inhibitors Influence Cabozantinib Outcomes in Metastatic Kidney Cancer?


AACR 2021 Overall Survival Update From IMmotion151 in Advanced Kidney Cancer


Is Plasma KIM-1 Linked to Recurrence Risk After Nephrectomy


CRP Flare Response and Response to Nivolumab in Kidney Cancer


Brain Metastasis 15 Years After Radical Nephrectomy for Renal Cell Carcinoma Case Report


ASCO 2021 42-Month Follow-up of Pembrolizumab Plus Axitinib in Advanced Clear Cell Kidney Cancer


ASCO 2021 Impact of Lenvatinib-Based Therapy on Quality of Life in Renal Cell Carcinoma


ASCO 2021 Telaglenastat Plus Cabozantinib in Advanced Renal Cell Carcinoma


Do Patient Demographics Influence Treatment Decisions in Kidney Cancer


Nivolumab Alone and in Combination Therapy for Non–Clear Cell Kidney Cancer


Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma


CheckMate 920 Nivolumab Plus Ipilimumab for Renal Cell Carcinoma With Brain Metastases


MET Driven Kidney Cancer: Combination of Durvalumab and Savolitinib Under Study


JAVELIN Renal 101 Trial: Second-Line Treatment With Axitinib Plus Avelumab in Kidney Cancer


Immunotherapy and Cytoreductive Nephrectomy in Metastatic Kidney Cancer


Temporary Treatment Cessation Versus Continuation in Advanced Kidney Cancer


Can Modified Dosing Schedule of Ipilimumab Improve Tolerability in Renal Cell Carcinoma


Patient-Reported Outcomes From KEYNOTE-564 With Adjuvant Pembrolizumab for Kidney Cancer


METEOR Trial of Cabozantinib Versus Everolimus in Advanced Kidney Cancer: Prognostic Plasma Biomarkers


Correlation Between Analgesic Use and Risk of Renal Cell Carcinoma


SITC 2021: Interaction of Immune Checkpoint Inhibitors for Renal Cancer and COVID-19 Vaccination


Transcriptome Sequencing and T-Cell Receptor Spatial Mapping in Renal Cell Carcinoma


Final Survival Analysis of Immotion151: Atezolizumab Plus Bevacizumab in Metastatic Kidney Cancer


ASCO GU 2022: International Study of Cabozantinib for Treating Brain Metastases From Kidney Cancer


ASCO GU 2022: Long-Term Follow-up From CheckMate 214 With Nivolumab Plus Ipilimumab in Advanced Kidney Cancer


ASCO GU 2022: Do Sarcomatoid Features Affect Outcomes With Nivolumab Plus Cabozantinib for Kidney Cancer?


Extended Follow-up Supports Nivolumab Plus Cabozantinib in Renal Cell Carcinoma


Phase III Trial to Combine Immune Checkpoint Inhibitors With or Without Nephrectomy


AACR 2022: Predictive Properties of Zinc Finger Protein in Clear Cell Renal Cell Carcinoma


Is Immunotherapy Combination Effective as Salvage Treatment in Metastatic Renal Cell Carcinoma?


Rare Case of Renal Cell Carcinoma in Patient With Tuberous Sclerosis Complex


Does Drinking Coffee Reduce the Risk of Renal Cell Carcinoma


Do Sex-Specific Hormones Influence Outcomes With Immunotherapy for Kidney Cancer


Renal Cell Carcinoma Risk After Hysterectomy or Oophorectomy


First-Line Pembrolizumab Monotherapy in Advanced Non–Clear Cell Renal Cell Carcinoma


Nivolumab for Sarcomatoid Renal Cell Carcinoma With Metastases Case Report


Does Ferroptosis-Related Gene Portend Poor Prognosis in Kidney Renal Clear Cell Cancer


Primary Tumor Size and Survival After Surgery in Kidney Cancer


Metastatic Kidney Cancer Targeted Therapy Plus Immune Checkpoint Inhibition


Can Combination of Targeted Therapy and Immunotherapy Improve Surgical Outcomes in Renal Cell Carcinoma


Expression of AOX 1in Clear Cell Renal Cell Carcinoma


Role of miR-198 in Suppressing Growth of Renal Cell Carcinoma


TRIM Family Proteins and Development of Renal Cell Carcinoma


Can Axitinib Amid Immunotherapy Sequences Improve Outcomes in Renal Cell Carcinoma


Rare Cases of SARS–CoV-2 Infection Inducing Spontaneous Regression of Metastatic Kidney Cancer


ASTRO 2020 Risk of Radiation-Induced Heart Disease in Patients Treated for Breast Cancer


SITC 2020: Cyclophosphamide Prior to Pembrolizumab in Metastatic Triple-Negative Breast Cancer


De-escalated Weekly Dose of Palliative Breast Radiotherapy


SABCS 2020: Does Breast Cancer Influence Mortality From COVID-19


SABCS 2020 Initial PENELOPE-B Results With Palbociclib-Based Therapy for Primary Breast Cancer


SABCS 2020: Patient-Reported Outcomes With Atezolizumab Plus Chemotherapy in Triple-Negative Breast Cancer


Comparison of Number of Fractions of Accelerated Partial Breast Irradiation


SABCS 2020: Pembrolizumab Plus Chemotherapy in Metastatic Triple-Negative Breast Cancer


Trop-2 Expression and Sacituzumab Govitecan in Triple-Negative Breast Cancer


Tesetaxel Plus Reduced-Dose Capecitabine in Metastatic Breast Cancer


Androgen Receptor Modulator in ER-Positive AR-Positive Breast Cancer


Addition of Entinostat to Endocrine Therapy for Advanced Breast Cancer


MONALEESA-7 Update Ribociclib Plus Endocrine Therapy for Advanced Breast Cancer


Neoadjuvant Regimens Compared in Advanced Operable Breast Cancer


Risk of Breast Cancer in Common Drugs for Diabetes and Obesity


Are Type 2 Diabetes and Metformin Use Associated With Breast Cancer Risk?


AACR 2021 Neratinib Plus Fulvestrant for HER2-Mutant Metastatic Breast Cancer


Is Surveillance Mammography Necessary in Older Breast Cancer Survivors


AACR 2021 Using ctDNA Changes to Predict Response to Palbociclib-Based Therapy for Breast Cancer


Distant Lymph Node Metastases From Breast Cancer: A Regional Disease


Predicting Response to Combination Therapies for Breast Cancer Brain Metastases


Can Healthy Plant-Based Diets Decrease the Risk of Breast Cancer


Eribulin and Pembrolizumab Combination in Triple-Negative Breast Cancer


ESMO Breast 2021 Does Clinical Benefit From Endocrine Therapy Differ by Risk Group


ESMO Breast 2021 Distinct Gene Signatures Associated With Pathologic Complete Response


ESMO Breast 2021 Atezolizumab Plus Carboplatin for Metastatic Invasive Lobular Cancer


ASCO 2021 COVID-19 Outcomes and Breast Cancer by Racial/Ethnic Group


Treatment Implications of Breast Tumors Switch to HER2-Low Status in Recurrence


ASCO 2021 Long-Term Survival With Palbociclib Plus Fulvestrant in Advanced Breast Cancer


ASCO 2021 Neoadjuvant Talazoparib Active in Germline BRCA1/2-Mutated HER2-Negative Breast Cancer


ESMO 2021 COVID-19 Vaccination in Patients With Breast Cancer


DESTINY-Breast03 Trial of T-DXd Versus T-DM1 in HER2-Positive Breast Cancer


ESMO 2021 Long-Term Overall Survival With Letrozole Plus Ribociclib in Advanced Breast Cancer


Neoadjuvant Giredestrant Versus Anastrozole in Postmenopausal Women With Early Breast Cancer


Update From KEYNOTE-355 on Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer


ESMO 2021: Subgroup Analysis of Asian Patients Treated With T-DM1 for Breast Cancer


ESMO 2021: Interim Phase II Results With Dalpiciclib Plus Pyrotinib in HER2-Positive Breast Cancer


Updated Survival Results From DESTINY-Breast01 of T-DXd in Metastatic Breast Cancer


ASTRO 2021 COVID-19 Pandemic and Radiotherapy Patterns for Breast Cancer


Can Systems-Based Intervention Reduce Racial Gaps in Treatment of Breast Cancer


Accelerated Partial-Breast Irradiation Fractions and Breast Cosmesis


30-Year Analysis of Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer


Appropriate Timing of Radiotherapy After Mastectomy for High-Risk Breast Cancer


SITC 2021: Cellular Study of Malignant Pleural Effusions and Metastatic Breast Cancer


Phase III Trial Explores Internal Mammary Node Irradiation in Node-Positive Breast Cancer


SITC 2021 Anti-CD47 Immunotherapy Under Study for Reducing Breast Cancer Brain Metastasis


SABCS 2021 Neoadjuvant and Adjuvant Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer


Final Results of PALLAS Trial on Palbociclib Plus Endocrine Therapy in HER2-Negative Breast Cancer


KEYNOTE-355 Final Results of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer


Final Results of Phase II Trial of Eftilagimod Alpha in Metastatic Breast Cancer


Menopausal Status and Outcomes of Endocrine Therapy With or Without Chemotherapy for Breast Cancer


Advanced Breast Cancer: Overall Survival Subgroup Analysis From MONALEESA-2 Trial


How Does Pembrolizumab Impact the Tumor Microenvironment of Triple-Negative Breast Cancer?


Pilot Trial Evaluates Mutation-Reactive TILs and Immunogenicity in Metastatic Breast Cancer


ER-Positive Breast Cancer: Novel Protein Receptor Predictive of Response to Treatment?


How Common Is Overdiagnosis of Breast Cancer in the United States?


ASBrS 2022: Study Finds COVID-19 Restrictions Delayed Care for Many Women With Breast Cancer


AACR 2022: Impact of Comorbidities on the Overall Health of Older Breast Cancer Survivors


MONALEESA-2 Trial: Overall Survival With Ribociclib Plus Letrozole in Advanced Breast Cancer


AACR 2022: Does Hormone Receptor–Positive ESR1-Mutated Breast Cancer Respond to CDK4/6 Inhibition?


AACR 2022: What Can Be Learned From Man’s Best Friend About Aggressive Breast Cancer?


Balancing Efficacy and Toxicity in Treatment Delivery in HER2-Positive Breast Cancer


Can Addition of T-DM1 Improve Outcomes Over Standard Treatment in HER2-Positive Breast Cancer?


Can Immune Checkpoint Inhibitors Improve Pathologic Complete Response in Breast Cancer?


Leptomeningeal Metastasis of Breast Cancer: CSF Analysis May Improve Diagnosis and Treatment


ASCO 2022: Survival Update From PALOMA-2 With Palbociclib Plus Letrozole in Advanced Breast Cancer


ASCO 2022: Endocrine Therapy Plus Ribociclib for CDK4/6 Inhibitor–Resistant Metastatic Breast Cancer


Is the Risk of Breast Cancer in Men Influenced by Infertility?


Supine Versus Prone Breast Radiotherapy: Impact on the Skin of Women With Large Breasts


ESMO 2022: METEORA-II Trial Evaluates Triplet Regimen in Advanced Breast Cancer


SABCS 2022: monarchE Update on Endocrine Therapy Plus Abemaciclib for High-Risk Breast Cancer


SABCS 2022: Update From First-in-Human Trial of ARV-471 in Advanced Breast Cancer


SABCS 2022: Risk of Contralateral Breast Cancer Among Carriers of Germline Pathogenic Variants


SABCS 2022: Mechanisms of Resistance to CDK4/6 Inhibitors in Aggressive Breast Cancer


An Index of Sensitivity to Endocrine Therapy Under Study in Male Breast Cancer


Is Radiotherapy Necessary for All Women After Breast-Conserving Surgery for Breast Cancer?


AACR 2023: Can Heparan Sulfate Induce Durable Responses to Chemotherapy in Triple-Negative Breast Cancer?


ASCO 2023: The Potential of ctDNA to Predict Future Relapse in a Subtype of Breast Cancer


ASCO 2024: Longest Reported Follow-up of Fertility and Pregnancy Among Survivors of Breast Cancer


ASCO 2024: DESTINY-Breast06 Update on T-DXd vs Chemotherapy in Metastatic Breast Cancer


ASCO 2024: Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer


ASCO 2024: Novel Antibody-Drug Conjugate Under Study in Advanced Triple-Negative Breast Cancer


Racial Disparities and Impact of COVID-19 on Clinical Outcomes in Breast Cancer


Breast Cancer Subtypes: How Do Epithelial Cells and Macrophages Interact?


Can Early Patient Education Help to Manage Adverse Effects From Breast Cancer Treatment?


ESMO 2024: Adding SBRT to Immunotherapy and Chemotherapy in High-Risk Breast Cancer


ASCO Quality 2024: Can Socioeconomic Status Influence Breast Cancer Severity?


ESMO 2024: Chemotherapy-Free Immunotherapy for Immunogenic Triple-Negative Breast Cancer


ASTRO 2024: Noninferiority Trial of Hypofractionated Radiation Schedules After Mastectomy


ASTRO 2024: Hypofractionation With Simultaneous Integrated Boost in Breast Cancer


ASTRO 2024: French Trial of Radiotherapy Plus T-DXd in HER2-Positive Breast Cancer


Multilevel Chronic Stress and the Tumor Immune Environment: Is There a Connection?


Novel CDK2/4 Inhibitor Under Study in Metastatic Breast Cancer


Radiotherapy Strategy for Enhancing Immunotherapy for Triple-Negative Breast Cancer


SITC 2024: Overcoming PARP Inhibitor Resistance in BRCA1-Mutated Breast Cancer


SABCS 2024: HER3-DXd Under Study in HR-Positive, HER2-Negative Early Breast Cancer


SABCS 2024: T-DXd vs Chemotherapy in Previously Treated Metastatic Breast Cancer


SABCS 2024 Correlation of Biomarkers With Outcomes in Early Triple-Negative Breast Cancer


Can Some Patients Avoid Chest Wall Irradiation After Mastectomy?


Breast Tumor Microenvironment Differences in Black Women


Stem Cell–Derived Dendritic Cells With Radiotherapy Under Study in Preclinical Breast Cancer Models


Can Behavioral Therapy Relieve Headaches for Breast Cancer Survivors


5-Year Results With Intraoperative Radiotherapy Among Black Women With Breast Cancer


Dietary Acid Load and Associated Mortality After Breast Cancer on Long Island, New York


KEYNOTE-522: Event-Free Survival With Pembrolizumab in Triple-Negative Breast Cancer


Can Cytosine and Guanine Nucleotide Pairs Influence Epigenetic Aging of Breast Tissue?


Is Etirinotecan Pegol Superior to Chemotherapy in Treating Brain Metastases From Breast Cancer?


Plant-Derived Extracellular Nanovesicles: Biomedical Approach to Triple-Negative Breast Cancer


Link Between Breast Cancer Stage and Breast Cancer–Specific Death


Novel Treatment Combinations With Imlunestrant for Advanced Breast Cancer


ASTRO 2020 Pericardial Effusion and Survival With Radiation Therapies in Locally Advanced NSCLC


SITC 2020: Vactosertib Plus Durvalumab in PD-L1–Positive NSCLC


SITC 2020 Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma


Stereotactic Body Radiotherapy for Larger Lung Tumors


Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer


WCLC 2020 Genomic Analysis of Women With Lung Cancer Who Never Smoked


WCLC 2020 Updated Overall Survival With Atezolizumab in NSCLC From IMpower110


WCLC 2020 Pembrolizumab Plus Chemotherapy for Metastatic NSCLC


WCLC 2020 3-Year Survival Update on Pembrolizumab for Locally Advanced or Metastatic NSCLC


Updated USPSTF Recommendation on Lung Cancer Screening


Brigatinib in Alectinib-Resistant ALK-Positive NSCLC


EGFR Inhibitor Mefatinib Under Study in Advanced EGFR-Mutant NSCLC


RATIONALE 303 Update on Tislelizumab Versus Docetaxel in Advanced NSCLC


Does Performance Status Correlate With Survival in Pembrolizumab-Treated Patients With NSCLC


ASCO 2021 EGFR- and MET-Based Biomarkers of Resistance to Therapy for Lung Cancer


ASCO 2021 LAG-3 Protein Plus Pembrolizumab Under Study in Metastatic Lung Cancer


Preliminary Results With Novel EGFR Inhibitor for EGFR-Mutated Lung Cancer


Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC


Does Antibiotic Therapy Impact Outcomes to Chemoimmunotherapy in NSCLC


Primary Results From DESTINY-Lung01 on T-DXd in HER2 Mutated Lung Cancer


Patterns of Relapse From IMpower010 of Atezolizumab Versus Best Supportive Care in NSCLC


ESMO 2021: Use of Poziotinib for NSCLC Harboring HER2 Exon 20 Mutations Under Study


ESMO 2021: Bevacizumab Versus the Biosimilar MIL60 in Nonsquamous NSCLC


Immunotherapy Plus Chemoradiation Followed by Nivolumab Maintenance in Unresectable NSCLC


SITC 2021: Immunomodulatory Effects of Neoadjuvant Nivolumab and Chemotherapy in NSCLC


Early-Phase Study Results of LN-145 Monotherapy in NSCLC


Tumor Biopsy Analysis of Anticancer Vaccine–Treated Patients With Advanced NSCLC


Anti-TIGIT Monoclonal Antibody Plus Pembrolizumab Focus of Phase II Study in NSCLC


Potential Correlation Between Stage Shift and Survival Among Patients With NSCLC


Use of Patritumab Deruxtecan in EGFR Inhibitor–Resistant NSCLC


STS 2022: Surgical Approaches to Lobectomy for NSCLC: Lymph Node Upstaging and Overall Survival


STS 2022: Does High-Intensity Surveillance After Surgery Improve Outcomes in Stage I NSCLC?


STS 2022: Radiomic Approach to Predicting Histologic Subtype of Early-Stage Lung Adenocarcinoma


STS 2022: Surgical Wedge Resection Versus Stereotactic Radiation Therapy for in Situ NSCLC


Role of Bupivacaine in Pain Management After Lobectomy for Early-Stage Lung Cancer


Does Adding Radiotherapy to Immunotherapy Improve Outcomes in Metastatic NSCLC?


Novel CRISPR Approach May Uncover Regulators of Lung Cancer Development


Does Long-Term Exposure to Wildfires Increase the Risk for Lung Cancer?


IFCT-1803 LORLATU Cohort Evaluates Lorlatinib in Advanced ALK-Rearranged NSCLC


WCLC 2022: Interim Analysis of Overall Survival With Atezolizumab in Resected NSCLC From IMpower010


WCLC 2022: Noninferiority Trial of Lobar or Sublobar Resection for Peripheral NSCLC


WCLC 2022: SHAWL Study Focuses on Sexual Dysfunction in Women With Lung Cancer


WCLC 2022: Early Data on Sotorasib Plus an SHP2 Inhibitor in KRAS-Mutated NSCLC


ASTRO 2022: 2-Year KEYNOTE-799 Update on Pembrolizumab Plus Chemoradiotherapy in Stage III NSCLC


ASTRO 2022: Stereotactic Ablative Radiotherapy Plus Durvalumab for Early-Stage NSCLC


SITC 2022: Is Immunotherapy Feasible for Patients Living With HIV and NSCLC?


SITC 2022: Outcomes of Combination Therapy for Advanced NSCLC Stratified by KRAS Status


Can CD8-Positive, FoxP3-Positive Cells Predict Immunotherapy Response in NSCLC?


Study Finds Link Between Guideline Adherence for Imaging and Survival in NSCLC


AACR 2024: Can Ferroptosis Induction Overcome Chemoresistance in NSCLC?


ASCO Plenary Series: Phase II Study of Glecirasib in KRAS G12C–Mutated NSCLC


Does Thoracic Radiotherapy Induce Changes in Cardiac Morphology and Function?


Can Oligoprogressive NSCLC Be Treated With Radiotherapy After Immunotherapy?


Case Study: Pathologic Complete Response After Triple-Induction Therapy for NSCLC


STK11 Mutations and Immunotherapeutic Efficacy in NSCLC


ASCO 2024: Early Results From EVOKE-01 of Sacituzumab Govitecan in Metastatic NSCLC


ASCO 2024: Subcutaneous vs Intravenous Amivantamab Combined With Lazertinib in NSCLC


ASCO 2024: Updated IMpower010 Survival Analysis of Atezolizumab in PD-L1–Positive NSCLC


Patient-Reported Outcomes: Wedge Resection vs Uniportal Thoracoscopic Segmentectomy for Peripheral NSCLC


EGFR-Mutated NSCLC: MRD Detection and Adjuvant Osimertinib


Is a Fixed 2-Year Duration of Pembrolizumab Treatment Safe in Advanced NSCLC?


End-of-Life Care in Lung Cancer: Systemic Therapy Variability Among Oncologists


LIBRETTO-431: East Asian Subgroup Analysis of Selpercatinib in RET-Positive NSCLC


WCLC 2024: Ivonescimab vs Pembrolizumab in First-Line Treatment of PD-L1–Positive NSCLC


ESMO 2024: Update on Encorafenib Plus Binimetinib in BRAF V600E–Mutated NSCLC


WCLC 2024: Survival Update From TROPION-Lung01 on Dato-DXd vs Docetaxel in NSCLC


ASCO Quality 2024: Can the Expansion of Medicaid Improve Clinical Outcomes in NSCLC?


ASCO Quality 2024: Upfront Liquid Biopsy May Guide Therapeutic Options in NSCLC


Can Tusamitamab Ravtansine Improve Survival in CEACAM5-High NSCLC?


ASTRO 2024: Can SBRT to the Primary Tumor Site Improve Outcomes in Metastatic NSCLC?


Wedge Resection or Lobectomy: Comparing Survival Benefits in NSCLC


SITC 2024: Can Machine Learning Identify Treatment-Specific Outcomes and Biomarkers in NSCLC?


Stage III NSCLC: Midtreatment PET-Adapted Radiotherapy Dose Escalation


Study Plans to Evaluate Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC


Combination of Chemotherapy, Immunotherapy, and Radiotherapy for NSCLC With Brain Metastases


Can ORACLE Predict Survival and Chemotherapy Response in Lung Adenocarcinoma?


Can the Combination of CDK4 and MEK Inhibitors Reduce Resistance to Lung Cancer Therapy?


Can Neuronal Autoantibodies Influence Cognitive Impairment in Patients With Lung Cancer


Locally Advanced NSCLC Outcomes With Metformin Plus Chemoradiotherapy


Sintilimab Plus Pemetrexed and Platinum for NSCLC Updated ORIENT-11 Study Results


Final Overall Survival Results From APOLLO of Aumolertinib in Advanced NSCLC


Trends in the Cost of Agents Used to Treat Metastatic NSCLC


NOP56 and mTOR Cooperation Mechanism in KRAS-Mutant Lung Cancer


New Research Supports HERC5 as a Potential Metastasis Suppressor Gene in NSCLC


Survival and Immune Checkpoint Inhibitor Efficacy in KRAS-Mutated NSCLC


Can Comprehensive Genomic Profiling Influence Clinical Outcomes in Advanced NSCLC?


Intensity-Modulated Radiotherapy and Survival Outcomes in Locally Advanced NSCLC


INCREASE STUDY: Immunotherapy Plus Chemoradiotherapy for Operable NSCLC


Can Technologic Advance Identify Lung Cancer in Exhaled Breath?


Does Methylmalonic Acid Weaken Antitumor Immunity in Patients With Lung Cancer?


Researchers Explore the Role of NCAPG in the Growth and Metastasis of NSCLC


PACE and OPTIC Trials Focus on Ponatinib in Resistant Chronic-Phase CML


Does Imatinib Halt Disease Progression in Pediatric Patients With CML


Case Study Ovarian Cancer Disguised as Preeclampsia in a Pregnant Woman


Can Genomic Instability Predict Response to PARP Inhibitors in Ovarian Cancer?


Can Targeting SMARCA4 Overcome Ovarian Cancer Immune Evasion?


Predicting Prognosis in HGSOC: Focus on Myeloid-Driven T-Cell Exhaustion


Targeting Immune Cell Molecules May Improve Chemotherapy Response in HGSOC


Can Flutamide-Induced Restoration of miRNA-449 Reduce the Risk of Ovarian Cancer?


Copyright © 2026 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.